Innate Pharma
Open
$1.45
Prev. Close
$1.45
High
$1.47
Low
$1.45
Market Snapshot
$128.67M
-0.94
$226.43M
163
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
emptyResult
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Recently from Cashu
Innate Pharma Advances Immunotherapy with Robust Pipeline and Strategic Partnerships
Innate Pharma Strengthens Position in Immunotherapy Development Innate Pharma SA, based in Marseille, France, announces its total shares outstanding and voting rights as of December 31, 2024, in compl…
Innate Pharma Advances Cancer Immunotherapy with Innovative Research and Strategic Collaborations
Innate Pharma's Commitment to Cancer Immunotherapy Development Innate Pharma SA, a clinical-stage biotechnology firm based in Marseille, France, underscores its commitment to advancing cancer immunoth…
Innate Pharma's Growth Strategy: Innovation and Collaboration in Oncology Treatment
Innate Pharma Unveils Ambitious Growth Strategy Focused on Innovation and Collaboration Innate Pharma SA is charting a transformative path in oncology and autoimmune disease treatment with its newly u…
Innate Pharma's Innovative Growth Strategy Targets Cancer and Autoimmune Therapies
Innate Pharma Unveils Bold Growth Strategy Focused on Innovative Therapies Innate Pharma SA announces a robust growth strategy centered on enhancing innovation in immunotherapy, particularly through i…